Evidence map›Paper›PMID 31530043›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2019

Novel 4-arylaminoquinazolines bearing

Yaling Zhang, Li Chen, Xiabing Li, Li Gao, Yunxia Hao, Baolin Li, Yaping Yan

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Design, synthesis andJournal of enzyme inhibition and medicinal chemistry · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yaling ZhangNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University , Xi'an , P. R. China.ORCID http://orcid.org/0000-0002-7122-0268
Li ChenSchool of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Xiabing LiSchool of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Li GaoSchool of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Yunxia HaoSchool of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Baolin LiNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University , Xi'an , P. R. China.ORCID http://orcid.org/0000-0001-9836-0036
Yaping YanNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University , Xi'an , P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, four novel 4-arylaminoquinazoline derivatives with

Indexed as

Antineoplastic AgentsApoptosisCell CycleCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorErbB ReceptorsHumansMolecular Docking SimulationMolecular StructureProtein Kinase InhibitorsQuinazolinesStructure-Activity RelationshipTumor Cells, CulturedAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsQuinazolinesantiproliferative activities-diethyl(aminoethyl)amino moietymolecular dockingQuinazoline derivativeswild type epidermal growth factor receptor tyrosine kinase (EGFR-TK)

Identifiers

PMID31530043
PMCPMC6758725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.